While upregulation of SRRM4 has been reported to promote neuroendocrine prostate cancer through alternative splicing [38,39], SRRM4 is seen to decrease in expression within the tumor proper compared with the leading edge and infiltrating tumor in GBM based on RNA sequencing data from the IVY Glioblastoma Atlas Project [40]. This evidence concerns the gene SRRM4 and neoplasm.